Investment Highlights

  • LC101 development was completed and led by the inventor of the branded Doxil®
  • Signed strategic agreement with tier 1 pharma company to commercialize LC101 in the U.S. market
  • ANDA submitted to FDA in collaboration with U.S. strategic partner
  • U.S. marketing authorization expected – 2H/20
  • FDA accredited, cGMP manufacturing facility secured to support commercial launch
  • Overall $500m ww market opportunity with very few competitors due to high entry barriers
    (i.e. complex nano-drug)

Upcoming Catalysts

  • LC101 ANDA submission to FDA – 2H/19
  • U.S. marketing authorization expected – 2H/20
  • Further international expansion (e.g. China) of LC101 via on-going BD efforts
  • Pipeline of Liposomal products based on Ayana’s platform technology are in development